Lung Cancer Study Published in JAMA Oncology Shows Guardant360 Outperforms Tissue Biopsy Alone in Identification of Targetable Mutations
Researchers from the
"This landmark study is the first to show that a comprehensive and highly sensitive blood test, Guardant360, almost doubled the number of targetable mutations found with tissue genotyping alone, and should be used before the start of treatment so that all seven guideline-recommended genomic targets can be rapidly assessed," said
In one of the largest studies of its kind, oncologists used the Guardant360 test to evaluate 323 patients for clinically actionable mutations that guide initial and subsequent treatment decisions – either in combination with tissue biopsy or alone for 101 patients who were unable to undergo a tissue biopsy or for whom a tissue biopsy produced incomplete results. In all, among 229 patients that had concurrent plasma and tissue next generation sequencing (NGS) or were unable to complete tissue testing, Guardant360 found targetable mutations in nearly twice as many patients as the tissue biopsy alone, producing insights that guided standard of care treatment for 82 patients (36 percent) compared with 47 patients (20.5 percent).
Of the patients with targetable mutations identified, 67 were treated with a corresponding targeted therapy, with 42 patients being evaluated for response. Of those 42 patients, 37 demonstrated either a complete response, partial response or stable disease at the time of evaluation.
"The benefit seen in this study, especially among treatment-naïve patients, is extremely encouraging," noted
Since its introduction in 2014, the Guardant360 assay has been ordered more than 70,000 times to help inform which therapy may be effective for advanced stage cancer patients with solid tumors. It has been reviewed by more than 80 peer-reviewed publications, which address its analytical validity, clinical validity, and clinical utility in multiple tumor types. For advanced NSCLC, Guardant360 is covered by
View original content to download multimedia:http://www.prnewswire.com/news-releases/lung-cancer-study-published-in-jama-oncology-shows-guardant360-outperforms-tissue-biopsy-alone-in-identification-of-targetable-mutations-300731846.html
Investors, Lynn Lewis or Carrie Mendivil, firstname.lastname@example.org; or Media, Josh Wein or Ian Stone, email@example.com